Skip to content
Screener

Beta Bionics BBNX Return on equity

Return on equity at other companies

Insulet logo
InsuletPODD
26%+6.8pp
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
-48%-17.5pp
Medtronic logo
MedtronicMDT
9.8%+0.4pp
AdaptHealth logo
AdaptHealthAHCO
-5.2%-10.8pp
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
124.5%+12.7pp

Other financials

Income statement

See full
Revenue$32.0M+37.8%
Gross profit$18.9M+51.2%
Operating income-$25.6M-28.7%
Net income-$23.4M-38.7%
EPS (diluted)-$0.53-35.9%

Balance sheet

See full
Cash & equivalents$44.3M+26.4%
Total debt$6.5M-2.6%
Total equity$256.4M-15.0%
Total assets$292.4M-11.4%

Cash flow

See full
Operating cash flow-$14.6M-7.6%
CapEx$1.0M-41.6%
Free cash flow-$15.7M-1.9%

Valuation

See full
Market cap$715.34M+15.1%
Enterprise value$677.53M+14.2%
P/S6×-2.0×

Profitability

See full
Gross margin58.3%+4.4pp
Operating margin-69.8%-8.0pp
Net margin-61.3%-15.8pp
FCF margin-51.6%-13.4pp

Returns & leverage

See full
Debt / equity0×0.0×
Current ratio8.9×-5.8×

Where this comes from

Calculated from Beta Bionics’s reported figures.

net income/total stockholders equity=-26.2%

Based on trailing twelve months.

The source filing: Beta Bionics’s 10-Q, filed July 29, 2026. Open the filing →

Filed
Jul 29, 2026, 4:20 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-323777

FAQ

What is Beta Bionics's return on equity?
Beta Bionics (BBNX) reported return on equity of -26.2% in Q2 2026.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

Ask your AI about Beta Bionics's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude